A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Blood vessel research offers insights into new treatments for eye diseases
28 May 2014
Leukaemia drugs could help to improve treatments for blindness caused by abnormal blood vessel growth in the eye, finds new UCL research.
The study, published in the Journal of Experimental Medicine, raises the possibility that medication prescribed for leukaemia could also be used to improve vision in patients with age-related macular degeneration, diabetic retinopathy and other diseases caused by abnormal growth of blood vessels in the eye.
“Blood vessels normally form in developing foetuses to deliver oxygen to growing organs, or in adults when organs are deprived of oxygen due to conditions such as diabetes, stroke or heart attack,” explains Professor Christiana Ruhrberg of the UCL Institute of Ophthalmology, who led the study. “Even though the growth of new blood vessels aims to restore organ health, blood vessels often grow abnormally in adults. For example, in diseases such as age-related-macular degeneration and diabetic retinopathy, abnormal eye vessels leak blood and fluids, causing vision loss.”
Because the formation of new blood vessels depends on the molecular signal vascular endothelial growth factor (VEGF), patients with age-related macular degeneration or diabetic retinopathy are treated with drugs that block VEGF. This treatment involves an injection into the eye to deliver the drug and works very well for most patients, but some patients have side effects due to the injection and others stop responding to the treatment after initial success and their vision deteriorates again.
“We discovered an alternative mechanism that regulates blood vessel growth and does not depend on VEGF,” says Professor Ruhrberg. “It involves the activation of a molecule called neuropilin 1 (NRP1) by connective tissue components in the eye. The NRP1 pathway then coveys signals inside the blood vessel cells via another molecule termed ABL1, and this process stimulates blood vessel growth.”
The researchers discovered that a medicine, which safely treats some forms of leukaemia, also blocks the NRP1/ABL1 pathway in blood vessels and can therefore be used to curb their abnormal growth in the mouse eye. In cancer patients, this medicine is delivered in tablet form rather than through n injection, raising the possibility that this drug could be taken safely at home to treat blood vessel disease in the eye.
UCL Business PLC, the technology transfer office for UCL, has patented this technology and is seeking partners. Please contact Dr Rachel Hemsley for further information, email@example.com